Detailing the First Non-Immunosuppressive Therapy Approved for IgAN
Time: 9:00 am
day: Conference Day One
Details:
- Uncovering its unique mechanism of action of blocking both endothelin and angiotensin receptors
- Highlighting the study design and targeted population
- Discussing the potential for its use in combination therapy
